'Kras mutant' diaporamas de présentation

Predictive biomarker validation in practice: Lessons from real trials

Predictive biomarker validation in practice: Lessons from real trials. Daniel Sargent, PhD Division of Biomedical Statistics and Informatics Mayo Clinic, Rochester MN U Penn Conference, April 29, 2009. Prognostic Marker.

552 views • 40 slides

Eric Van Cutsem*

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Eric Van Cutsem*

491 views • 26 slides

Mace L. Rothenberg, M.D.

Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR Inhibitors. Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research. Conflict of Interest Disclosure. Consultant or Advisory Role. Stock Ownership. Biomarkers in CRC Management.

439 views • 21 slides

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC. Reviewer: Dr. Scott Berry Date posted: October 2011.

232 views • 10 slides

A549 KRAS mutant G12S LKB1 null M CDKN2A (p16) M CDKN2a (p14) SMARCA4

283 views • 5 slides

Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with Cetuximab GI-biomarker 0902. Enrollment: 94. SD. PD. PR.

141 views • 1 slides